Treats schizophrenia. ANDA 89903, held by Hikma Pharmaceuticals. Prochlorperazine Edisylate.
As of Nov 21, 2026, ANDA 89903 (Prochlorperazine Edisylate), held by Hikma Pharmaceuticals, was first approved by FDA on Aug 29, 1989, with 16 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 29, 1989 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prochlorperazine EdisylateEQ 5MG BASE/ML · injectable;injection | Prochlorperazine Edisylate | Rx |
| Feb 19, 2025 | Supplement 33Labeling · Standard review | Approved | None posted |
| Mar 21, 2017 | Supplement 21Labeling · Standard review | Approved | None posted |
| Aug 26, 2016 | Supplement 20Labeling · Standard review | Approved | None posted |
| Dec 3, 2010 | Supplement 18Labeling | Approved | |
| Jun 29, 2009 | Supplement 17Labeling | Approved | None posted |
| Nov 25, 2008 | Supplement 16Labeling | Approved | None posted |
| Jul 14, 2004 | Supplement 10Labeling | Approved | None posted |
| Nov 13, 2002 | Supplement 9Manufacturing | Approved | None posted |
| May 16, 2000 | Supplement 8Manufacturing | Approved | None posted |
| Oct 7, 1999 | Supplement 7Manufacturing | Approved | None posted |
| Aug 12, 1997 | Supplement 6Manufacturing | Approved | None posted |
| Aug 1, 1996 | Supplement 5Manufacturing | Approved | None posted |
| Nov 18, 1993 | Supplement 4Manufacturing | Approved | None posted |
| Sep 1, 1993 | Supplement 3Labeling | Approved | None posted |
| Sep 28, 1992 | Supplement 2Manufacturing | Approved | None posted |
| Sep 15, 1989 | Supplement 1Labeling | Approved | None posted |
| Aug 29, 1989 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters